Avista Capital Partners Gp, Ll Sells 12,128 Shares of Lantheus Holdings, Inc. (LNTH) Stock
Lantheus Holdings, Inc. (NASDAQ:LNTH) major shareholder Avista Capital Partners Gp, Ll sold 12,128 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $17.05, for a total value of $206,782.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Avista Capital Partners Gp, Ll also recently made the following trade(s):
- On Tuesday, August 15th, Avista Capital Partners Gp, Ll sold 40,779 shares of Lantheus Holdings stock. The shares were sold at an average price of $17.06, for a total value of $695,689.74.
- On Monday, August 14th, Avista Capital Partners Gp, Ll sold 87,939 shares of Lantheus Holdings stock. The shares were sold at an average price of $17.40, for a total value of $1,530,138.60.
Shares of Lantheus Holdings, Inc. (NASDAQ LNTH) traded down 6.82% during trading on Wednesday, hitting $15.70. The stock had a trading volume of 1,387,452 shares. The company has a market cap of $586.40 million, a PE ratio of 21.45 and a beta of 0.91. Lantheus Holdings, Inc. has a 12-month low of $5.68 and a 12-month high of $20.45. The stock’s 50 day moving average is $18.08 and its 200-day moving average is $14.43.
Lantheus Holdings (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.18. The business had revenue of $88.83 million during the quarter, compared to the consensus estimate of $80.56 million. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The business’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.24 earnings per share. Analysts forecast that Lantheus Holdings, Inc. will post $1.12 earnings per share for the current year.
A number of large investors have recently bought and sold shares of LNTH. Trexquant Investment LP purchased a new stake in Lantheus Holdings during the first quarter worth about $332,000. Nordea Investment Management AB increased its stake in Lantheus Holdings by 23.7% in the first quarter. Nordea Investment Management AB now owns 127,700 shares of the medical equipment provider’s stock worth $1,596,000 after buying an additional 24,500 shares during the period. Systematic Financial Management LP purchased a new stake in Lantheus Holdings during the first quarter worth about $1,314,000. Bank of New York Mellon Corp increased its stake in Lantheus Holdings by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock worth $856,000 after buying an additional 4,084 shares during the period. Finally, FNY Partners Fund LP purchased a new stake in Lantheus Holdings during the first quarter worth about $174,000. 71.53% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have recently commented on LNTH. Jefferies Group LLC reaffirmed a “buy” rating and issued a $22.00 price target (up previously from $18.00) on shares of Lantheus Holdings in a research note on Wednesday, August 2nd. Zacks Investment Research raised Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $18.00 price target on the stock in a research note on Thursday, August 3rd. Credit Suisse Group upped their price target on Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Finally, Cantor Fitzgerald began coverage on Lantheus Holdings in a research note on Monday, July 17th. They issued an “overweight” rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $18.60.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.